Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Follow-Up Questions
¿Quién es el CEO de Adial Pharmaceuticals Inc?
Mr. Cary Claiborne es el President de Adial Pharmaceuticals Inc, se unió a la empresa desde 2021.
¿Qué tal es el rendimiento del precio de la acción ADIL?
El precio actual de ADIL es de $0.3603, ha increased un 0.11% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Adial Pharmaceuticals Inc?
Adial Pharmaceuticals Inc pertenece a la industria Pharmaceuticals y el sector es Health Care
¿Cuál es la capitalización bursátil de Adial Pharmaceuticals Inc?
La capitalización bursátil actual de Adial Pharmaceuticals Inc es $7.8M
¿Es Adial Pharmaceuticals Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 4 analistas han realizado calificaciones de análisis para Adial Pharmaceuticals Inc, incluyendo 2 fuerte compra, 5 compra, 2 mantener, 0 venta, y 2 fuerte venta